The Trump rally is holding the bulk of last week's big gains. The last two Stock Of The Day picks are among five names ...

Artificial intelligence giants Alphabet and Nvidia have earned a spot on the IBD Breakout Stocks Index. And both Google stock ...

Brooke Abbott Abron faced significant barriers to diagnosis and adequate care for Crohn's disease, rooted in systemic racism ...

Nanoparticles that turn inflammation into propulsion power deliver targeted IBD treatment, enhancing precision and efficacy.

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Alcohol can worsen Crohn’s disease symptoms, but the impact varies from person to person. It may depend on what and how much ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.